← Leaderboards
Joseph R Garlich
Semafore Pharmaceuticals, Inc.
$828,753
Attributed
$828,753
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$828,753 · 3
By mechanism
R41$446,752 · 1
R43$382,001 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsChemical SynthesisCombinatorial ChemistryDrug Delivery SystemsDrug Design /Synthesis /ProductionHydroxyapatitesIntegrinsLaboratory MouseLigandsMetalsMolecular DynamicsNuclear MedicineP53 Gene /ProteinReceptor BindingBone MarrowChelating AgentsChelation TherapyChemical ModelsChemical Registry /ResourceBiodegradable ProductBiotechnologyDrug MetabolismCalcium Binding ProteinGene Induction /Repression
Grant awards (4)
Bone Targeting of Degradable Drug-Filled Nanoparticles$221,401
R43 · FY2003 · CA
Chelate Based Scaffolds (Chelabody) In Tumor Targeting$225,111
R41 · FY2002 · CA
Targeted Delivery of Protectant p53 Inhibitors$160,600
R43 · FY2002 · CA
Chelate Based Scaffolds (Chelabody) In Tumor Targeting$221,641
R41 · FY2001 · CA